U.S. flag

An official website of the United States government

Filters

See more specimen types...
See more states

Other countries

See more countries

Results: 21 to 40 of 58

Tests names and labsConditionsGenes, analytes, and microbesMethods

Cylindromatosis, familial, 132700, Autosomal dominant (Familial cylindromatosis) (CYLD gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

Cylindromatosis, familial, 132700, Autosomal dominant (Familial cylindromatosis) (CYLD gene) (Sequence Analysis-All Coding Exons) (Prenatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

NeoTYPE® Discovery Profile for Solid Tumors

NeoGenomics Laboratories NeoGenomics Laboratories, Inc.
United States
1315
  • I Immunohistochemistry
  • F Fluorescence in situ hybridization (FISH)
  • C Sequence analysis of the entire coding region

ProvSeq 523

Providence St. Joseph Health Molecular Genomics Laboratory Providence St Joseph Health
United States
1523
  • C Sequence analysis of the entire coding region

Cancer Panel

PreventionGenetics, part of Exact Sciences
United States
134119
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Oncological diseases panel _v.2.0

CGC Genetics Unilabs
Portugal
1205
  • C Sequence analysis of the entire coding region

Brooke-Spiegler syndrome , Trichoepithelioma, multiple familial, 1 , Cylindromatosis, familial (sequencing and CNV analysis of CYLD gene)

CGC Genetics Unilabs
Portugal
11
  • C Sequence analysis of the entire coding region

Melanoma and Other Skin Cancers Panel

Mendelics
Brazil
144
  • C Sequence analysis of the entire coding region

Hereditary Cancer Panel (Complete)

Mendelics
Brazil
1264
  • C Sequence analysis of the entire coding region

OnkoSight Advanced Plasma Cell Myeloma NGS Panel

BioReference Health
United States
150
  • C Sequence analysis of the entire coding region

OnkoSight Advanced NGS Multiple Myeloma Panel

BioReference Health
United States
150
  • C Sequence analysis of the entire coding region

OnkoSight Advanced Comprehensive Solid Tumor Panel (DNA/RNA)

BioReference Health
United States
1523
  • C Sequence analysis of the entire coding region

OnkoSight Advanced 523 Gene NGS Panel

BioReference Health
United States
1523
  • C Sequence analysis of the entire coding region

HEREDITARY CANCER EXOME PANEL

Laboratorio de Genetica Clinica SL
Spain
1249
  • E Sequence analysis of select exons

MI Tumor Seek Hybrid

Caris Life Sciences
United States
1591
  • R RNA analysis
  • C Sequence analysis of the entire coding region

OncoAlly™ Solid Tumor Analysis

Variantyx, Inc.
United States
1433
  • D Deletion/duplication analysis
  • X Mutation scanning of select exons
  • R RNA analysis

Solid Tumor Expanded Panel

Quest Diagnostics Nichols Institute San Juan Capistrano
United States
1523
  • I Microsatellite instability testing (MSI)
  • R RNA analysis
  • C Sequence analysis of the entire coding region

Cylindromatosis, familial: Full gene sequencing

CEN4GEN Institute for Genomics and Molecular Diagnostics
Canada
11
  • C Sequence analysis of the entire coding region

Brooke-Spiegler syndrome: Full gene sequencing

CEN4GEN Institute for Genomics and Molecular Diagnostics
Canada
11
  • C Sequence analysis of the entire coding region

Frontotemporal dementia and/or amyotrophic lateral sclerosis 8: Full gene sequencing

CEN4GEN Institute for Genomics and Molecular Diagnostics
Canada
11
  • C Sequence analysis of the entire coding region

Results: 21 to 40 of 58

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.